Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2023 08:01 ET | Source: Mainz BioMed NV

Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations

Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
October 18, 2023 08:01 ET | Source: Mainz BioMed NV

Mainz Biomed Presents Groundbreaking Results of ColoFuture Study

Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
October 11, 2023 08:01 ET | Source: Mainz BioMed NV

Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark

Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
October 05, 2023 08:01 ET | Source: Mainz BioMed NV

Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit

Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
October 04, 2023 08:01 ET | Source: Mainz BioMed NV

Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania

Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
September 27, 2023 08:01 ET | Source: Mainz BioMed NV

Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology

Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
September 20, 2023 03:01 ET | Source: Mainz BioMed NV

Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference

BERKELEY, Calif. and MAINZ, Germany, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
September 13, 2023 03:01 ET | Source: Mainz BioMed NV

Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%

Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense) BERKELEY, Calif. and MAINZ, Germany, Sept. 13, 2023 (GLOBE NEWSWIRE) --...
September 05, 2023 03:01 ET | Source: Mainz BioMed NV

Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market

BERKELEY, Calif. and MAINZ, Germany, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
August 29, 2023 03:01 ET | Source: Mainz BioMed NV

Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference

BERKELEY, Calif. and MAINZ, Germany, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...